Q1 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
GROWTH
KesimptaⓇ continues strong launch trajectory doubling sales vs. PY
Kesimpta
Sales evolution
USD m, % cc
US weekly NBRX1
350
Ex-US
US
300
+100%
250
384
89
200
150
195
100
295
172
50
тим
0
Q1 2022
Q1 2023
Sept 2020
Mar 2023
Global sales +100% (cc)²
US: Growing faster than market1,2
TRX +89% vs. PY (market +1%)
NBRX +60% vs. PY (market -8%)
B-cell NBRX share -50% of MS market
KesimptaⓇ NBRx share ~14% of MS market
Europe: Strong launch momentum³
65% of population with access to Kesimpta
>18k patients treated, thereof >1/3 naive patients
Confident in future growth
Significant room to grow: only 40% of MS patients
on B-Cell therapy in US1,2
Compelling product profile: 1 minute a month dosing
from home/anywhere4; 5 year efficacy 5 and safety data 6,7
See page 94 for references 1-7.
TRX total prescriptions.
NBRX-new to brand prescription.
15 Investor Relations | Q1 2023 Results
NOVARTIS | Reimagining MedicineView entire presentation